| Comment: Sweet clover - from toxin to treatment John Bradley
 pp 3-3
 In 1940, the agent that caused ‘sweet  clover disease’, a haemorrhagic  affliction of cattle that had eaten improperly  cured silage or hay made from sweet clovers,  was purified from spoiled hay. The agent  was identified the following year as 3,3’-  methylenebis(4-hydroxycoumarin) by  researchers at the Wisconsin Agricultural  Experiment Station of the University of  Wisconsin–Madison, leading to the  synthesis of a number of  analogues, one of which  was warfarin.
 | 
						| Warfarin management in haemodialysis patients Timothy Sadler, Kelvin Bao, Sanjay KK Ojha and Lisa C Willcocks
 pp 4-5
 Patients on haemodialysis may be anticoagulated  with warfarin for a number of conditions,  including atrial fibrillation, previous  venous thromboembolic disease and dialysis  access thrombosis. In any patient treated with  warfarin, the benefits that go with prevention  of thromboembolic disease have to be offset  against the risk of bleeding. Patients with endstage  renal failure who are treated with warfarin  have an increased risk of bleeding. This  risk is difficult to quantify, as no bleeding risk  scoring systems have been validated in this  population specifically.
 | 
						| Warfarin management in advanced kidney disease Kathrine Parker, Jecko Thachil and Sandip Mitra
 pp 6-8
 In the general population, warfarin has been  shown to be a highly effective therapy for the  treatment and prophylaxis of thromboembolic  disease.However, to date, there are no studies  to validate its clinical effectiveness in the endstage  renal disease population.  Safe warfarin treatment requires appropriate  monitoring to maintain the international normalised  ratio (INR) within a narrow therapeutic  range. An INR that falls within 0.5 of the target  value is deemed acceptable. Marked deviations  above and below the INR range are associated  with excessive bleeding and under-anticoagulation  respectively. The frequency of monitoring  can be variable and is dependent  on the stability of both the prior  measurements and the patient’s  medical condition.
 | 
						| Kidney policy matters Donal J O’Donoghue
 pp 9-9
 The NHS remains a turbulent place and a bit of  a political football. One could think it is more  about the government, British Medical Association  or Royal College of Nursing – or commissioning,  regulation and inspections – than the  health of the nation. Of course, all these are  necessary for the efficient and effective functioning  of healthcare services, but our shared  purpose is to add value for individuals and populations  by reducing the impact of disease and  providing care to manage its consequences, including  high-quality end-of-life care.
 | 
						| Painful legs in patients with type 1 diabetes and chronic kidney disease Gorav N Wali, Ramesh B Naik and Matthew Gibson
 pp 10-14
 Painful legs in diabetic patients have a broad  range of differential diagnoses, including cellulitis,  necrotising fasciitis, deep vein thrombosis,  haematoma, myositis, tumour and trauma.  Two of the more rare causes of painful legs are  diabetic muscle infarction and diabetic pyomyositis.  Both can present in a very similar  fashion, but require different treatments and  can result in markedly different outcomes.  They tend to occur in patients with microvascular  complications of diabetes, such as diabetic  nephropathy, and thus are likely to  present to the renal physician. Despite this,  there are few reports in the renal literature.
 | 
						| What I tell my patients about renal diets for children with CKD Pearl Pugh
 pp 15-18
 Changes to the diet are recommended in all  patients with chronic kidney disease (CKD).  One distinct factor that sets children apart  from adults is the fact that they are still  growing. The growth issue must be  championed in the dietary prescription,  which will require frequent review by family  and specialised paediatric renal dietitians.  Many years ago, before the advances in renal  replacement therapy, dialysing a newborn with CKD  was a technological challenge.
 | 
						| Awareness of organ donation in the South Asian community Adnaan Haq, Haseebullah Wardak, Haroen Sahak, Naaila Haq and David Oliviera
 pp 19-21
 The South Asian community in the UK is the  most under-represented population among  organ donors. The South Asian community  makes up a mere 1–2% of the donors on  the NHS organ donor register, despite the fact  that this population group is more likely to require  certain transplants. For example, South  Asians are three times more likely than the  general population to require kidney transplants,  due to their increased susceptibility to  chronic conditions such as hypertension and  diabetic nephropathy.
 | 
						| An Ethnic Liaison Support Worker for South Asian renal patients John Stoves, Tahira Akhtar, Vicki Hipkiss, Ramla Mumtaz, Tony Coman and Chris Lacey Investigation
 pp 22-25
 A large number of patients with advanced  chronic kidney disease in Bradford are  of South Asian origin. Effective delivery of care  for these patients demands a consistently high  standard of communication between patients,  their families and renal unit staff. Communication  may be problematic for a number of reasons,  including language barriers and an  incomplete appreciation of important cultural  or religious beliefs. In 2010, we were successful  in applying to the British Kidney Patient Association  for funding to employ an Ethnic  Liaison Support Worker (ELSW). The ELSW  is able to engage with and support patients, relatives  and other members of the multidisciplinary  team.
 | 
						| Survey of patients with advanced CKD receiving active supportive care Rachel E Davison, Therese Wood and Alison L Brown
 pp 26-28
 Patients with advanced chronic kidney disease  (CKD) are known to have a high symptom burden,  reported to be comparable to terminal  cancer. With an aging population and a  greater awareness of CKD, more people referred  to specialist nephrology clinics have  multiple co-morbidities and impaired functional  levels. Not all these patients will  progress to end-stage renal disease, but many  will experience distressing symptoms from  their renal insufficiency.
 | 
						| What you need to know about transplantation Nicholas Palmer
 pp 29-31
 A transplant is widely regarded as the ‘gold  standard’ for a person approaching end-stage  renal failure. For some, this may be a pre-emptive  transplant (to avoid dialysis) with a live  donor, while for others already on dialysis, it is  an opportunity to regain control of their life  and body. Either way, a transplant is a gift of  life, underpinned by love, bravery, generosity  and morality, delivered with the dexterity,  skill, diligence and care of the transplant team  and nursing staff, with its long-term survival  secured by research from around the globe.
 |